• Rova-T; antibody–drug conjugate SC16LD6.5
    • An antibody–drug conjugate containing an antibody (SC16) directed against an as-of-yet undisclosed protein and conjugated to the cytotoxic agent D6.5 that will selectively bind to the target on tumor cell surfaces and cause DNA damage
    • Phase 3 metastatic NSCLC; phase 1b/2 medullary thyroid cancer, melanoma, neuroendocrine carcinoma, and neuroendocrine prostate cancer
    • Recommended phase 3 dose: 0.3 mg/kg IV every 42-day cycle
    • Half-life: 10 to 14 days
    • Common side effects: Thrombocytopenia, fatigue, rash, serosal effusions, capillary leak syndrome, peripheral edema
    (Kavalerchik et al., 2017)
    Other topics in Targeted and Immunotherapy Agents